Oncternal Therapeutics Stock Performance
| ONCT Stock | USD 8.77 0.22 2.57% |
Oncternal Therapeutics has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of 0.51, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Oncternal Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oncternal Therapeutics is expected to be smaller as well. Oncternal Therapeutics right now holds a risk of 4.28%. Please check Oncternal Therapeutics value at risk, and the relationship between the jensen alpha and skewness , to decide if Oncternal Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Oncternal Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable fundamental indicators, Oncternal Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return (0.18) | Five Day Return (0.64) | Year To Date Return (22.88) | Ten Year Return (99.56) | All Time Return (99.95) |
Last Split Factor 1:20 | Dividend Date 2019-06-10 | Last Split Date 2024-01-08 |
1 | Oncternal Therapeutics, Inc. Given Average Rating of Hold by Brokerages - Defense World | 02/09/2024 |
2 | Acquisition by Richard Vincent of 14200 shares of Oncternal Therapeutics subject to Rule 16b-3 | 02/15/2024 |
3 | Disposition of 980 shares by Robert Wills of Oncternal Therapeutics at 9.04 subject to Rule 16b-3 | 02/23/2024 |
4 | Sale by Robert Wills of 980 shares of Oncternal Therapeutics | 02/27/2024 |
5 | Oncternal Therapeutics Q4 Earnings Snapshot | 03/07/2024 |
6 | Earnings call Oncternal reports Q4 results and clinical updates | 03/08/2024 |
7 | Acquisition by Chase Leavitt of 28750 shares of Oncternal Therapeutics at 0.31 subject to Rule 16b-3 | 03/12/2024 |
8 | Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape New Treatment Options for Prostate Cancer | 03/15/2024 |
9 | Acquisition by Larue William R of 25000 shares of Oncternal Therapeutics at 0.3553 subject to Rule 16b-3 | 03/18/2024 |
10 | Acquisition by Robert Wills of 6914 shares of Oncternal Therapeutics at 8.4759 subject to Rule 16b-3 | 03/28/2024 |
11 | Oncternal therapeutics director buys 58.6k in company stock | 04/01/2024 |
12 | Acquisition by Robert Wills of 3086 shares of Oncternal Therapeutics at 8.9613 subject to Rule 16b-3 | 04/08/2024 |
13 | Oncternal therapeutics director buys 27.7k of company stock - Investing.com | 04/10/2024 |
14 | Oncternal shares price target cut by H.C. Wainwright on Q4 earnings miss | 04/15/2024 |
15 | Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 12 Study of ONCT-534 for the Treatment of RR Metastatic Castration-Resistant Prostate Cancer | 04/18/2024 |
| Begin Period Cash Flow | 37.1 M |
Oncternal |
Oncternal Therapeutics Relative Risk vs. Return Landscape
If you would invest 897.00 in Oncternal Therapeutics on January 25, 2024 and sell it today you would lose (20.00) from holding Oncternal Therapeutics or give up 2.23% of portfolio value over 90 days. Oncternal Therapeutics is currently generating 0.055% in daily expected returns and assumes 4.2771% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Oncternal, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncternal Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncternal Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncternal Therapeutics, and traders can use it to determine the average amount a Oncternal Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0129
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ONCT | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.28 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Oncternal Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncternal Therapeutics by adding it to a well-diversified portfolio.
Oncternal Therapeutics Fundamentals Growth
Oncternal Stock prices reflect investors' perceptions of the future prospects and financial health of Oncternal Therapeutics, and Oncternal Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncternal Stock performance.
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (32.44) % | ||||
| Current Valuation | (8 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.93 X | ||||
| Price To Sales | 35.44 X | ||||
| Revenue | 785 K | ||||
| Gross Profit | (31.49 M) | ||||
| EBITDA | (41.71 M) | ||||
| Net Income | (39.48 M) | ||||
| Cash And Equivalents | 78.9 M | ||||
| Cash Per Share | 1.48 X | ||||
| Total Debt | 318 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.78 X | ||||
| Book Value Per Share | 10.19 X | ||||
| Cash Flow From Operations | (32.16 M) | ||||
| Earnings Per Share | (13.43) X | ||||
| Market Capitalization | 25.94 M | ||||
| Total Asset | 36.73 M | ||||
| Retained Earnings | (197.78 M) | ||||
| Working Capital | 30.86 M | ||||
| Current Asset | 27.27 M | ||||
| Current Liabilities | 6.3 M | ||||
About Oncternal Therapeutics Performance
To evaluate Oncternal Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Oncternal Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Oncternal Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Oncternal Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Oncternal's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.000012 | 0.000013 | |
| Return On Tangible Assets | (1.07) | (1.13) | |
| Return On Capital Employed | (1.32) | (1.39) | |
| Return On Assets | (1.07) | (1.13) | |
| Return On Equity | (1.31) | (1.38) |
Things to note about Oncternal Therapeutics performance evaluation
Checking the ongoing alerts about Oncternal Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncternal Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncternal Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 785 K. Net Loss for the year was (39.48 M) with loss before overhead, payroll, taxes, and interest of (31.49 M). | |
| Oncternal Therapeutics currently holds about 78.9 M in cash with (32.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.48. | |
| Oncternal Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 12 Study of ONCT-534 for the Treatment of RR Metastatic Castration-Resistant Prostate Cancer |
- Analyzing Oncternal Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncternal Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Oncternal Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncternal Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncternal Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncternal Therapeutics' stock. These opinions can provide insight into Oncternal Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.Note that the Oncternal Therapeutics information on this page should be used as a complementary analysis to other Oncternal Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Oncternal Stock analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Oncternal Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.43) | Revenue Per Share 0.267 | Quarterly Revenue Growth 0.737 | Return On Assets (0.49) | Return On Equity (0.87) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.